Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 195
Journal of Integrative Medicine ; (12): 453-462, 2022.
Article in English | WPRIM | ID: wpr-939897


OBJECTIVE@#Rheumatoid arthritis (RA) progression is associated with the balance of T-regulatory (Treg) and T-helper 17 (Th17) cells, while the role of microRNAs (miRs) in regulating Treg/Th17 cell balance has not been clarified. This study aimed to assess whether moxibustion could regulate Treg/Th17 cell balance by modulating the miR-221/suppressor of cytokine signaling 3 (SOCS3) axis in the RA mouse model.@*METHODS@#A mouse model of collagen-induced arthritis (CIA) was established in male DBA/1J mice. Twenty-two days after CIA induction, the mice received daily treatment with moxibustion for 12 times. Pathological scores were assessed according to the levels of synovial hyperplasia. The expression levels of cytokines interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), IL-17 and IL-10 were analyzed in serum by enzyme-linked immunosorbent assay. The cluster of differentiation 4 (CD4+) splenocytes was analyzed by fluorescence-activated cell sorting. The expression levels of RA-related miRs and target genes were subsequently detected, and the target of miR-221 was confirmed by the dual-luciferase reporter assay.@*RESULTS@#It was revealed that moxibustion treatment decreased the pathological scores and downregulated the expression levels of IL-1β, IL-6, TNF-α, IFN-γ and IL-17, while upregulated the expression level of IL-10. The Treg/Th17 cell balance was regulated by moxibustion treatment. The expression level of miR-221 was suppressed by moxibustion treatment. Furthermore, SOCS3 was found as the direct target of miR-221, which mediated the function of moxibustion by regulating the Treg/Th17 cell balance.@*CONCLUSION@#Moxibustion therapy regulated the Treg/Th17 cell balance by modulating the miR-221/SOCS3 axis in the RA mouse model.

Animals , Arthritis, Experimental/therapy , Arthritis, Rheumatoid/therapy , Cytokines , Disease Models, Animal , Interleukin-10 , Interleukin-17 , Interleukin-6 , Male , Mice , Mice, Inbred DBA , MicroRNAs/genetics , Moxibustion , T-Lymphocytes, Regulatory , Th17 Cells/pathology , Tumor Necrosis Factor-alpha
Rev. Cuerpo Méd. Hosp. Nac. Almanzor Aguinaga Asenjo ; 14(4): 510-522, Dic. 29, 2021. tab, graf
Article in Spanish | LILACS, BIGG | ID: biblio-1367689


La Artritis Reumatoide (AR) tiene adversas consecuencias en la salud su diagnóstico temprano y manejo óptimo requiere recomendaciones basadas en evidencia de alta calidad adaptadas a cada sistema de salud. Objetivo: Proveer recomendaciones clínicas basadas en evidencia para el diagnóstico y manejo inicial de la AR. Material y Métodos: Se conformó un grupo elaborador de la guía (GEG) que incluyó médicos especialistas y metodólogos. El GEG formuló 10 preguntas clínicas a ser respondidas por la presente GPC. Se realizaron búsquedas sistemáticas de la evidencia publicada en PubMed y CENTRAL entre diciembre 2017 a julio 2019 (revisiones sistemáticas y ­cuando fue considerado pertinente­ estudios primarios). Se seleccionó la evidencia de mayor calidad para responder cada una de las preguntas clínicas planteadas. La certeza de la evidencia fue evaluada usando la metodología Grading of Recommendations Assessment, Development, and Evaluation (GRADE) y en reuniones de trabajo periódicas, el GEG usó dicha metodología para revisar la evidencia y formular las recomendaciones, los puntos de buena práctica clínica y los flujogramas. Finalmente, la GPC fue aprobada con Resolución N° 132 ­ IETSI ­ ESSALUD ­ 2019. Resultados: La presente GPC abordó 10 preguntas clínicas, divididas en dos temas: diagnóstico y manejo. En base a dichas preguntas se formularon 16 recomendaciones (5 fuertes y 11 condicionales), 45 puntos de buena práctica clínica, y 3 flujogramas. Conclusión: El presente artículo resume la metodología y las conclusiones basadas en evidencias de la GPC para el diagnóstico y manejo inicial de la AR en EsSalud.

Rheumatoid arthritis (RA) has adverse health consequences its early diagnosis and optimal management requires high quality evidence-based recommendations tailored to each health system. Objective: To provide evidence-based clinical recommendations for the diagnosis and initial management of RA. Material and Methods: A guideline development group (GDG) was formed that included medical specialists and methodologists. The GEG formulated 10 clinical questions to be answered by this CPG. Systematic searches of the evidence published in PubMed and CENTRAL were performed between December 2017 and July 2019 (systematic reviews and -when considered relevant- primary studies). The highest quality evidence was selected to answer each of the clinical questions posed. The certainty of the evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology, and in periodic working meetings, the GEG used this methodology to review the evidence and formulate the recommendations, good clinical practice points, and flowcharts. Finally, the CPG was approved by Resolution No. 132 - IETSI - ESSALUD - 2019. Results: This CPG addressed 10 clinical questions, divided into two topics: diagnosis and management. Based on these questions, 16 recommendations (5 strong and 11 conditional), 45 points of good clinical practice, and 3 flowcharts were formulated. Conclusion: This article summarizes the methodology and evidence-based conclusions of the CPG for the diagnosis and initial management of RA in EsSalud.

Humans , Arthritis, Rheumatoid/therapy , Peru , Arthritis, Rheumatoid/diagnosis , Adrenal Cortex Hormones/therapeutic use , Drug Therapy, Combination
Säo Paulo med. j ; 139(2): 91-97, Mar.-Apr. 2021. tab, graf
Article in English | LILACS | ID: biblio-1290228


ABSTRACT BACKGROUND: Rheumatoid arthritis (RA) is a chronic disease with higher prevalence among women aged between 30 and 50 years and general prevalence of 1% worldwide. Interventions promoting improvement of quality of life for individuals with RA are required. Tai Chi appears to be a low-cost alternative, with studies showing positive results from this technique. However, regarding aspects of RA such as pain and sensitivity, studies remain inconclusive. OBJECTIVES: To compare the effectiveness of the Tai Chi method for treating patients diagnosed with rheumatoid arthritis, among systematic reviews. DESIGN AND SETTING: Overview of systematic reviews with Cochrane and non-Cochrane methodology. METHODS: Systematic reviews involving quasi-randomized and randomized clinical trials (RCTs) on use of Tai Chi, with no restrictions regarding the date and language of publication, were included. RESULTS: Three systematic reviews were included. The effects of Tai Chi associated with education and stretching exercises versus education and stretching were evaluated in these reviews. They showed that improvements in the variables of mood, depression and functional index were associated with use of Tai Chi. CONCLUSIONS: The findings suggest that clinical improvement was achieved, although not statistically significant with regard to pain and disease pattern, as assessed using the ACR20 measurement. Improvements relating to disability and quality of life were also seen. There was a low level of evidence and therefore caution in data analysis is recommended. The three studies included showed poor reliability for providing an accurate and complete summary of use of Tai Chi among people diagnosed with rheumatoid arthritis. PROSPERO: CRD42019125501.

Humans , Female , Adult , Middle Aged , Arthritis, Rheumatoid/therapy , Tai Ji , Quality of Life , Exercise Therapy , Systematic Reviews as Topic
West Indian med. j ; 69(1): 21-25, 2021. tab
Article in English | LILACS | ID: biblio-1341868


ABSTRACT Objective: Rheumatoid arthritis (RA) is a common autoimmune disease for which there is no known cure. Ultraviolet light can induce immunosuppressive effects. Our main objective was to ascertain whether a complementary treatment with phototherapy would improve changes in functional scales in patients with RA. Methods: Seven women with RA were enrolled for this study and submitted to phototherapy sessions with a 425-650 nm lamp. Results: The Karnofsky scale changed from requiring frequent medical care to being capable of normal activity with few symptoms or signs of disease (p = 0.018), the rheumatoid arthritis-specific quality of life questionnaire decreased abruptly from 29 to 0 points (p = 0.018), the Steinbrocker functional capacity rating changed from limited to little or none of the duties of usual occupation or self-care to complete ability to carry out all the usual duties without handicaps (p = 0.017). The pain was remitted after the treatment period. The acute inflammation variables showed a significant decrease after the indicated sessions, C-reactive protein (p = 0.042) and erythrocyte sedimentation rate (p = 0.018). Conclusion: The evaluated scales clearly show a benefit with the phototherapy in patients with RA. Thus, phototherapy seems to be a plausible complementary option to reduce the symptoms of RA.

Humans , Female , Adult , Middle Aged , Young Adult , Phototherapy , Arthritis, Rheumatoid/therapy , Prospective Studies , Longitudinal Studies , Treatment Outcome , Karnofsky Performance Status
Rev. chil. pediatr ; 91(4): 521-528, ago. 2020. tab
Article in Spanish | LILACS | ID: biblio-1138666


Resumen: Introducción: Al menos 50% de los pacientes pediátricos portadores de artritis idiopática juvenil (AIJ) continuará control en reumatología adulto. La clasificación de la Liga Internacional de Asociaciones de Reumatología (ILAR) vigente, actualmente en revisión, difiere de la clasificación de las artritis inflamatorias del adulto. Se ha reportado cambios de categoría en 10,8% de los pacientes durante el seguimiento. Objetivo: Analizar los pacientes con AIJ seguidos al menos 7 años para objetivar cambios de diagnós tico en la transición, e identificar factores de mal pronóstico funcional. Pacientes y Método: Estudio retrospectivo en base a registros clínicos. Se incluyó a la totalidad de los pacientes con AIJ controla dos en policlínico pediátrico del Hospital de Puerto Montt entre el año 2005 y 2017, que cumplieron siete o más años de seguimiento. Se realizó análisis descriptivo en base a variables clínicas: categoría diagnóstica, tiempo de evolución al diagnóstico, actividad clínica y serológica, y tiempo de evolución al inicio de la terapia farmacológica. Resultados: Se evaluaron 18 pacientes, 3 Oligo-articular (OA) persistente, 1 OA extendida, 4 Poli-articular (PA) factor reumatoide (FR) negativo, 4 PA FR positivo, 5 Sistémicas, 1 Psoriática, todos con seguimiento mayor a 7 años. Once de 18 niños fueron transfe ridos a adultos. Tres de 11 cambiaron de diagnóstico a Artritis Reumatoide (AR) más otra enferme dad autoinmune: Síndrome de Sjögren + Lupus eritematoso sistémico, Púrpura trombocitopénico inmune, Enfermedad autoinmune no clasificada y cinco de 11 niños de categoría ILAR: OA a Artritis reumatoide juvenil, OA extendida a PA FR negativo, 3 Sistémicas a PA FR negativo. Edad de inicio, formas poli-articulares, retrasos en diagnóstico y comienzo de terapia se asociaron a secuelas e infla mación persistente. Conclusiones: Ocho de once pacientes transferidos cambiaron denominación diagnóstica y/o presentaron otras enfermedades autoinmunes. Algunos factores de mal pronóstico deben mejorar.

Abstract: Introduction: At least 50% of pediatric patients with Juvenile Idiopathic Arthritis (JIA) will require continued fo llow-up in adult rheumatology. The present International League of Associations for Rheumatology (ILAR) classification, currently under revision, differs from its classification of inflammatory arthritis in adults. Category changes have been reported in 10.8% of patients during follow-up. Objective: To analyze JIA patients in follow-up for at least 7 years to detect diagnosis changes during transition to adult care, identifying factors of poor functional prognosis. Patients and Method: Retrospective study based on medical records of JIA patients seen at the pediatric polyclinic of the Puerto Montt Hospital between 2005 and 2017, who were monitored for at least 7 years. Descriptive analysis was performed according to clinical variables: diagnostic category, evolution before diagnosis, clinical and serological activity, and evolution before starting drug therapy. Results: We evaluated 18 pa tients, corresponding to 3 patients with persistent oligoarticular arthritis (OA), 1 with extended OA, 4 with polyarticular arthritis (PA) rheumatoid factor (RF) negative, 4 with PA RF positive, 5 with syste mic JIA, and 1 with psoriatic arthritis, all have had follow-up more than 7 years. 11 out of 18 patients transitioned to adult care. Three out of 11 patients changed diagnosis to Rheumatoid Arthritis (RA) plus another autoimmune disease such as Sjögren's Syndrome + Systemic Lupus Erythematosus, Immune thrombocytopenia, or unclassified autoimmune disease, and 5 out of 11 children changed ILAR category from OA to Juvenile Rheumatoid Arthritis, extended OA to PA RF negative, and 3 from Systemic arthritis to PA RF negative. Age of onset, polyarticular forms, delay in diagnosis, and the start of therapy were associated with sequelae and persistent inflammation. Conclusions: Eight of the eleven JIA patients who transitioned to adult care changed their diagnosis or presented other autoimmune diseases. Some factors of poor prognosis must improve.

Humans , Male , Female , Young Adult , Arthritis, Juvenile/diagnosis , Transition to Adult Care , Arthritis, Juvenile/classification , Arthritis, Juvenile/complications , Arthritis, Juvenile/therapy , Arthritis, Rheumatoid/classification , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/therapy , Prognosis , Arthritis, Psoriatic/complications , Arthritis, Psoriatic/diagnosis , Arthritis, Psoriatic/therapy , Retrospective Studies , Follow-Up Studies , Purpura, Thrombocytopenic, Idiopathic/complications , Purpura, Thrombocytopenic, Idiopathic/diagnosis , Purpura, Thrombocytopenic, Idiopathic/therapy , Aftercare , Disease Progression , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/therapy
Rev. cuba. reumatol ; 22(1): e111, ene.-abr. 2020.
Article in Spanish | LILACS, CUMED | ID: biblio-1126799


Introducción: Los pacientes mayores de 65 años son la parte de la población más afectada por las enfermedades reumáticas. El diagnóstico reumatológico en los ancianos se complica por las manifestaciones clínicas que imitan los cambios relacionados con la edad. Objetivo: Sintetizar los aspectos generales del manejo clínico, el diagnóstico y la terapéutica de las principales enfermedades reumáticas inflamatorias y no inflamatorias en este subgrupo de población. Desarrollo: Los principales trastornos musculoesqueléticos no inflamatorios que afectan a los adultos mayores son la osteoartritis, la osteoporosis y el dolor de espalda, mientras que las artritis inflamatorias predominantes comprenden la artritis reumatoide, la artropatía cristalina, la polimialgia reumática y las formas inflamatorias de la osteoartritis. Conclusiones: Para el diagnóstico y la terapéutica de las principales enfermedades reumáticas (inflamatorias y no inflamatorias) en este subgrupo de población, es necesario el enfoque multidisciplinar(AU)

Introduction: It is recognized that patients older than 65 years are the part of the population most affected by rheumatic diseases. The rheumatological diagnosis in the elderly is complicated by clinical manifestations, which mimic the changes related to age. Objective: To synthesize the general aspects of clinical management, diagnosis and therapy of the main rheumatic diseases inflammatory and non-inflammatory in this subgroup of the population. Development: The main non-inflammatory musculoskeletal disorders that affect older adults are osteoarthritis, osteoporosis and back pain, while the predominant inflammatory arthritis include rheumatoid arthritis, crystalline arthropathy, polymyalgia rheumatica and the inflammatory forms of osteoarthritis. Conclusions: It is vital for academics to be involved in the rheumatological aspects of aging and call attention to the imperative that is to promote reflective discussion within community medicine to address the impact of musculoskeletal problems that affect function and mobility of the elderly and immune dysregulation in aging, among other issues(AU)

Humans , Aged , Aged, 80 and over , Osteoarthritis/epidemiology , Polymyalgia Rheumatica , Arthritis, Rheumatoid/drug therapy , Rheumatic Diseases/diagnosis , Crystal Arthropathies , Osteoporosis/epidemiology , Arthritis, Rheumatoid/therapy , Back Pain
Rev. cuba. reumatol ; 22(1): e104, ene.-abr. 2020. tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1126797


Introducción: El ozono médico tiene eficacia clínica e incrementa la relación beneficio/riesgo en pacientes con artritis reumatoide tratados con la terapia combinada metotrexate + ozono. Hoy, la gamma glutamil transferasa se considera como un marcador de riesgo de enfermedades de una alta morbilidad y mortalidad, y tiene particular valor en la artritis reumatoide por desempeñar un papel patológico asociado al estrés oxidativo y a la remodelación ósea, lo que causa daño al cartílago y al hueso. Objetivo: Evaluar los efectos del ozono médico sobre los niveles de gamma glutamil transferasa. Métodos: Se estudiaron pacientes portadores de dos enfermedades artríticas: artritis reumatoide (n = 100; grupo tratado con metotrexate [n = 50] y grupo con metotrexate + ozono [n = 50]) y osteoartritis de rodilla (n = 40; grupo precondicionado con ozono antes de la artroscopía [n = 20] y grupo sin pretratamiento con ozono antes de la artroscopía [n = 20]). Los pacientes con artritis reumatoide fueron valorados con indicadores clínicos específicos, incluidos los niveles de anticuerpos contra péptidos cíclicos citrulinados, así como las concentraciones de glutatión reducido, importante antioxidante endógeno. Resultados: El ozono médico reguló la actividad sérica de gamma glutamil transferasa. Correlacionó de forma inversamente proporcional con los niveles de glutatión reducido que, a su vez, fue el único marcador redox que para los pacientes tratados con la terapia combinada metotrexate + ozono fue directamente proporcional con todas las variables clínicas evaluadas. Conclusión: Se debe considerar a la gamma glutamil transferasa un indicador de la eficacia clínica del ozono médico en las enfermedades estudiadas, por su doble función: biomarcador de estrés oxidativo e indicador de la remodelación patológica del hueso(AU)

Introduction: Medical ozone has demonstrated its clinical efficacy as well as the increase of beneficial/risk relationship in rheumatoid arthritis patients treated with metotrexate+ozone combined therapy. At present, gamma-glutamyl transpeptidase is considered as risk indicator of high morbimortality diseases. It has a special value in arthritis diseases due to its pathologic role associated to oxidative stress and in the abnormal bone remodeling processes. Objective: Assess the ozone medical effects on gamma-glutamyl transpeptidase levels. Method: Patients who suffered of two arthritic diseases: rheumatoid arthritis (n=100; Group treated with Metotrexate (n=50) and metotrexate+ozone (n=50) and knee osteoarthritis (n=40); Group preconditioned with ozone before arthroscopy (n=20) and Group without previous treatment with ozone before arthroscopy (n=20). Rheumatoid arthritis patients were assessed through specific clinic indicators which included antibodies against cyclic citrullinate peptides as well as reduced gluthatione concentrations which are an important endogenous antioxidant. Results: Medical ozone regulated serum gamma-glutamyl transpeptidase activity which correlated in inverse proportion to reduced glutathione levels which was the only one redox marker that correlated with all clinical variables (p < 0.05) when patients were treated with metotrexate+ozone. Conclusion: Gamma-glutamyl transpeptidase should be considered as biomarker of medical ozone clinical efficacy in rheumatoid arthritis and knee osteoarthritis due to GGT´s both pathologic functions: indicator of oxidative stress and abnormal bone remodeling processes(AU)

Humans , Ozone/therapeutic use , Arthritis, Rheumatoid/therapy , Osteoarthritis, Knee , gamma-Glutamyltransferase/analysis , Treatment Outcome , Combined Modality Therapy
Chinese Acupuncture & Moxibustion ; (12): 1211-1216, 2020.
Article in Chinese | WPRIM | ID: wpr-877588


OBJECTIVE@#To observe the effect of moxibustion on phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin protein (PI3K/Akt/mTOR) signaling pathway in the foot-pad synovial tissue in rats with rheumatoid arthritis (RA), and to explore the mechanism of moxibustion for treating RA.@*METHODS@#Forty healthy SD rats were randomly divided into a control group, a model group, a moxibustion group, a cigarette-moxibustion group and a medication group, 8 rats in each group. The RA model was established with subcutaneous injection of complete Freund's adjuvant (CFA) in the left hind foot-pad under wind, cold and wet environment in the model group, the moxibustion group, the cigarette-moxibustion group and the medication group. The rats in the moxibustion group were treated with moxibustion at "Zusanli" (ST 36) for 20 min; the rats in the cigarette-moxibustion group were treated with moxibustion of ordinary cigarette at "Zusanli" (ST 36) for 20 min; the rats in the medication group were treated with tripterygium glycosides suspension (0.8 mg/100 g) by gavage. All the intervention was given once a day for 15 days. The left hind foot-pad volume was measured before and after modeling and after 15-day intervention. After 15-day intervention, the serum levels of IL-17 and IL-23 were detected by ELISA method, and the expression levels of PI3K, Akt and mTOR in synovial tissue of left hind foot-pad were detected by Western blot method.@*RESULTS@#The volume of left hind foot-pad, the serum levels of IL-23 and IL-17 and the expression of PI3K, Akt and mTOR in synovial tissue of left hind foot-pad in the model group were higher than those in the control group (@*CONCLUSION@#Moxibustion may play a therapeutic effect on RA by inhibiting the level of IL-23, IL-17 and the activity PI3K/Akt/mTOR, and regulating inflammatory response and autophagy.

Animals , Arthritis, Rheumatoid/therapy , Moxibustion , Phosphatidylinositol 3-Kinases , Proto-Oncogene Proteins c-akt , Rats , Rats, Sprague-Dawley , Signal Transduction , Synovial Membrane , TOR Serine-Threonine Kinases
Brasília; Fiocruz Brasília;Instituto de Saúde de São Paulo; dez. 3, 2019. 34 p.
Non-conventional in Portuguese | LILACS, ColecionaSUS, MTYCI, PIE | ID: biblio-1118203


O yoga caracteriza-se como uma prática integrativa de origem oriental que combina posições corporais, técnicas de respiração, meditação e relaxamento. É indicada no tratamento de sistemas musculoesquelético, endócrino, respiratório, além de outros agravos à saúde, e estimula as funções cognitivas. Qual a eficácia/efetividade e a segurança do yoga para tratamento da dor aguda ou crônica em população adulta? As buscas foram realizadas nas bases de dados Pubmed, HSE-Health Systems Evidence, Epistemonikos, Portal Regional da BVS, HE-Health Evidence e Embase, em 27 de setembro de2019. Foram incluídas revisões sistemáticas (RS), com ou sem metanálises, publicadas em inglês, espanhol e português, e que que avaliavam o yoga no tratamento de dor crônica e aguda na população adulta e/ou idosa. Não houve restrição em relação ao ano de publicação. As estratégias de busca foram utilizadas com base na combinação de palavras-chave estruturadas a partir do acrônimo PICOS, usando os termos MeSH no Pubmed e DeCS na BVS, adaptando-os ao HSE, Epistemonikos, HE e Embase. A qualidade metodológica das revisões sistemáticas selecionadas foi avaliada segundo a ferramenta Assessing the Methodological Quality of Systematic Reviews(AMSTAR 2). De 693 artigos identificados, dez revisões sistemáticas foram selecionadas, oito delas com meta-análises. Com relação à qualidade metodológica, três revisões foram consideradas de qualidade moderada, duas de baixa qualidade e cinco de qualidade criticamente baixa. Na lombalgia crônica, a prática de yoga, quando comparada a atividades passivas, cuidado habitual, educação, atendimento médico padrão, controle de atenção, lista de espera, sem exercícios físicos, mostrou ser eficaz na diminuição da dor em curto, médio e longo prazos. Os resultados são mais consistentes com relação aos efeitos em curto e médio prazos. Na comparação de yoga com exercícios físicos as evidências resultam de poucos estudos e são controversas, mostrando benefício em curto e médio prazos no controle de lombalgia ou diferenças estatisticamente não significantes. Yoga, em comparação a intervenções passivas, sem exercícios físicos, mostrou ser benéfico também para melhorar quadros de incapacidade específica relacionada à lombalgia, em curto, médio e longo prazos. Além disso, houve melhora clínica dos casos de lombalgia a favor de yoga em curto e médio prazos. Na dor cervical crônica, as revisões mostraram evidências de efeitos benéficos de yoga para redução da dor quando comparado a cuidados habituais ou exercícios, entretanto não houve diferença com pilates ou medicina complementar e alternativa Da mesma forma, yoga mostrou-se superior a cuidados habituais e exercícios na redução da incapacidade relacionada dor cervical. A qualidade de vida e o humor melhoraram com yoga em relação a cuidados habituais. Yoga parece trazer benefícios também para pessoas com quadros de dor relacionados a osteoartrite e artrite reumatoide, fibromialgia, síndromes do túnel do carpo e do intestino irritável. No entanto, os resultados são menos consistentes. Com relação à segurança da prática de yoga, as evidências mostraram eventos adversos em geral sem gravidade. E quando comparado a exercícios não houve diferença no relato de eventos adversos. As revisões sistemáticas apresentaram resultados favoráveis à prática de yoga em relação aos cuidados habituais, particularmente nos casos de dor lombar e cervical. Há menos evidências acerca da superioridade do yoga em comparação a intervenções ativas. Em outras situações estudadas, como a dor associada a fibromialgia, osteoartrite, artrite reumatoide, síndromes do túnel do carpo e do intestino irritável, as evidências são menos consistentes. É importante ressaltar que as revisões sistemáticas incluídas nesta revisão rápida foram consideradas de baixa confiança na avaliação com a ferramenta AMSTAR 2. Além disso, os resultados têm como base estudos primários com amostras pequenas, com heterogeneidade na aplicação das intervenções, e considerável risco de viés. Isso remete à necessidade de se realizar ensaios clínicos, bem como revisões sistemáticas, com melhor qualidade metodológica

Humans , Adult , Middle Aged , Aged , Yoga , Acute Pain/therapy , Chronic Pain/therapy , Osteoarthritis/therapy , Arthritis, Rheumatoid/therapy , Carpal Tunnel Syndrome/therapy , Fibromyalgia/therapy , Treatment Outcome , Low Back Pain/therapy , Neck Pain/therapy , Irritable Bowel Syndrome/therapy
Rev. cuba. reumatol ; 21(3): e61, sept.-dic. 2019. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1093830


Introducción: la artritis reumatoide es una enfermedad inflamatoria, sistémica y crónica que afecta fundamentalmente el sistema osteomioarticular. Clinicamente se caracterizan por la presencia de dolor, inflamación, rigidez y deformidad. Estos elementos inciden en la aparición de la discapacidad funcional y en la disminución de la percepción de la calidad de vida relacionada con la salud. Objetivo: dar a conocer las ventajas del uso de la medicina natural en el tratamiento de la artritis reumatoide. Método: se realizó un estudio no experimental, descriptivo y retrospectivo en 115 pacientes a los cuales se les adicionó medicamentos naturales para el control de su enfermedad. Resultados: promedio de edad de 56,58 años con predominio de pacientes femeninas (69.60 por ciento), de color de la piel blanca (55.20 por ciento) y entre 50 y 59 años de edad (29.60 por ciento). La combinación de esteroides y methotrexate fue la más utilizad (55.20por ciento). La MNT se utilizó en el 62.4 por ciento de los pacientes con destaque para el servicio de hospitalización con una utilización del 79.19 por ciento. Los fitofármacos y la acupuntura fueron las modalidades más representadas. Conclusiones: existe un elevado por ciento de aplicación de la MNT en los esquemas terapéuticos de los pacientes con AR. Los fitofármacos y la acupuntura son las modalidades de mayor indicación. Los usuarios y prestadores mostraron elevados porcientos de aceptación al uso de la MNT en pacientes con enfermedades crónicas(AU)

Introduction: rheumatoid arthritis is an inflammatory, systemic and chronic disease that mainly affects the osteomyoarticular system. Clinically they are characterized by the presence of pain, inflammation, stiffness and deformity. These elements affect the appearance of functional disability and the reduction of the perception of the quality of life related to health. Objective: to present the advantages of the use of natural medicine in the treatment of rheumatoid arthritis. Method: a not experimental, descriptive, retrospective study was conducted in 115 patients to whom natural medicines were added to control their disease. Results: average age of 56.58 years with predominance of female patients (69.60 percent), white skin color (55.20 percent) and between 50 and 59 years of age (29.60 percent). The combination of steroids and methotrexate was the most used (55.20 percent). The NTM was used in 62.4 percent of the patients with a highlight for the hospitalization service with a utilization of 79.19 percent. The phytopharmaceuticals and acupuncture were the most represented modalities. Conclusions: there is a high percentage of application of NTM in the therapeutic schemes of patients with RA. The phytopharmaceuticals and acupuncture are the most indicated modalities. The users and providers showed high percentages of acceptance to the use of MNT in patients with chronic diseases(AU)

Humans , Arthritis, Rheumatoid/therapy , Quality of Life , Pharmaceutical Preparations , Methotrexate , Acupuncture/methods , Retrospective Studies
Rev. méd. Chile ; 147(6): 762-775, jun. 2019. tab, graf
Article in Spanish | LILACS | ID: biblio-1020725


Rheumatoid arthritis (RA) and chronic periodontitis (CP) may be related due to a bidirectional etiology. The evidence shows that CP could alter the clinical course of RA. We performed a systematic search to determine if CP alters the morbidity of RA, analyzing its clinical and molecular aspects. Of 552 initial articles found, 16 were selected for a thorough review. There is a greater prevalence of CP in patients with RA. Patients with RA have significantly higher values of periodontal clinical parameters than healthy controls. Arthritis activity is significantly greater in patients who suffer from CP and decreases with nonsurgical periodontal treatment. There is a significant relationship between the severity of CP and RA activity.

Humans , Male , Female , Arthritis, Rheumatoid/complications , Chronic Periodontitis/complications , Arthritis, Rheumatoid/physiopathology , Arthritis, Rheumatoid/therapy , Biomarkers , Case-Control Studies , Risk Factors , Chronic Periodontitis/physiopathology , Chronic Periodontitis/therapy
The Egyptian Journal of Hospital Medicine ; 77(3): 5148-5154, 2019. ilus
Article in English | AIM | ID: biblio-1272791


Background: Rheumatoid arthritis (RA) is the most common autoimmune disease. Ocular manifestations of RAvary and are mainly keratoconjunctivitis sicca, episcleritis, scleritis and keratitis. Antimalarial drugs [hydroxychloroquine (HCQ) and chloroquine (CQ)] have been used for the treatment of RA. Objective: The aim of this study was to study the ocular manifestations of rheumatoid arthritis and the complications of the use of hydroxychloroquine in treatment. Patients and methods: A prospective study that was conducted at Al-Zahraa University Hospital. The study included a total of 80 eyes of 40 patients. Patients were divided into two groups: Group (1) 20 RA patients not using HCQ treatment and group (2) 20 RA patients using HCQ treatment. All patients underwent complete ophthalmic examination including SD-OCT. Results: the most ocular manifestations found in patients were keratoconjunctivitis sicca (KCS) 93.8%, scleritis and episcleritis 2.5%, acute anterior uveitis (AAU) and sclerosing keratitis 1.3%. Regarding SD-OCT finding comparing between the two groups, we found signs of early HCQ retinopathy in patients of group 2 in the form of parafoveal and perifoveal thining compared to group 1. Conclusion: RA is associated with many extra-articular manifestations, HCQ and CQ used in treatment of RA have significant efficacy and safety, but with long duration of using can cause retinopathy, and follow up of patients is necessary to detect early retinopathy

Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/therapy , Egypt , Eye , Hydroxychloroquine
Prensa méd. argent ; 104(5): 240-243, jul2018.
Article in Spanish | LILACS, BINACIS | ID: biblio-1049296


El tratamiento de pacientes con artritis reumatoide (AR) debe ser temprano y agresivo para prevenir el daño articular y la discapacidad. Los fármacos no biológicos modificadoes de enfermedad, como el metotrexato, han sido utilizados par controlar la actividad de la enfermedad y para prevenir el daño de las articulaciones. Existen pacientes con AR resistentes al tratamiento con fármacos modificadores de la enfermedad y otros que no responden adecuadamente a la terapia con inhibidores de factores de necrosis tumoral. Nosotros describimos el caso de una paciente de sexo femenino de 77 años que se presentó al servicio de emergencias con fiebre, mucositis y mal estado general luego de recibir una dosis de abatacept. A su ingreso el laboratorio demostró: glóbulos blancos 500 cel/mm3, neutrófilos 150 cel/mm3, plaquetas 21000 cel/mm3, hematocrito 29%, VCM 81, LDH 314 UI/L, función renal y hepatograma normales. En el examen clínico se objetivaron ulceras y lesiones ampollares en mucosa yugal. El medulograma evidenció hipocelularidad, con disminución de las tres series. El informe anatomopatológico fue de médula ósea hipoplásica. Recibió tratamiento con factor estimulante de colonias de neutrófilos, ácido fólico y metilprednisona, con resolución del cuadro a los 3 días de instituido el tratamiento. Hasta nuestro conocimiento esta es la primera comunicación de pancitopenia asociada a abatacept es una paciente con artritis AR intolerante a metotrexato

Treatment of patient with rheumatoid arthritis (RA) should be early and aggressive to prevent joint injury and disability. Disease-modifying antirheumatic drugs (DMARDs) like methotrexate has been used as initial treatment toward the disease activity and to prevento joint damage. Some patients with RA are resistant to initial therapy with nonbiiologic DMARDs or TNF inhibitiors. We described a 77 years old women who presented to the emergency room with fever andoral lesions after been treated with abatacept. On examination patient appeared ill. She had oral ulcers. laboratory testing showed white cells count 500 cells per mm3, hematocrit 29 %, platelets count 21000 cells per mm3, LDH 314 U/l. Renal and liver functions were normal. Bone marrow showed decreased in the three cells lineages. Patient was treated with granulocyte colony-stimulating factor, folic acid, and prednisone. Patient improved her physical and laboratory features three days after admission. This case showed the rare association between pancytopenia and abatacept in a patient with RA

Humans , Female , Aged , Pancytopenia/diagnosis , Arthritis, Rheumatoid/therapy , Methotrexate/adverse effects , Methotrexate/therapeutic use , Abatacept/therapeutic use
Ciênc. Saúde Colet. (Impr.) ; 23(4): 1241-1253, abr. 2018. tab
Article in Portuguese | LILACS | ID: biblio-952630


Resumo A artrite reumatoide (AR) é uma doença crônica que afeta cerca de 1% da população adulta. No estudo de coorte histórica de pacientes de Minas Gerais, registrados no Sistema de Informações Ambulatoriais (SIA), em 2008-2013, foram identificados 11.573 indivíduos. A perspectiva foi a do financiador público e os valores observados como gastos do Sistema Único de Saúde (SUS) foram ajustados pelo Índice Nacional de Preços ao Consumidor Amplo (IPCA), de dezembro de 2015. O Etanercept foi o tratamento mais caro. A análise múltipla mostrou uma relação negativa entre o aumento das despesas e idade, sexo feminino e diagnóstico de entrada na coorte, e relação positiva para as variáveis Índice de Desenvolvimento Humano Municipal (IDH-M) e o uso de medicamentos bloqueadores do fator de necrose tumoral (ANTI-TNF). Este estudo identificou os fatores que têm impacto sobre o gasto com o tratamento medicamentoso da AR. Também apontou que métodos que permitem extrair dados demográficos e de gastos de sistemas de informação administrativos podem ser ferramentas importantes na construção de estudos econômicos capazes de subsidiar as avaliações econômicas de saúde, especialmente do ponto de vista da gestão.

Abstract Rheumatoid arthritis (RA) is a chronic condition that affects about 1% of the adult population. In a historical cohort of Minas Gerais State, 11,573 RA patients registered in the Outpatient Information System (SIA) between 2008 and 2013 were identified. For this study we adopted the public funding body's perspective and the values were adjusted by the national inflation index (IPCA) of December 2015. Etanercept was the most expensive treatment. The mean cohort age was 52 years old and most of the patients were women. Multiple regression analysis indicated a negative association between higher expenditure and age, female sex, and diagnosis at entry in the cohort and positive association between high expenditure and the Human Development Index (HDI) of the municipality and use of tumor necrosis factor agents. This study identified the factors that have an impact on RA drug treatment expenditure. Also, we showed that methods that enable extracting demographic and expenditure data of administrative information systems may represent important tools in the construction of economic studies to subsidize economic health evaluations, especially from the standpoint of the managers.

Humans , Male , Female , Adult , Aged , Arthritis, Rheumatoid/therapy , Health Expenditures , Antirheumatic Agents/administration & dosage , National Health Programs/economics , Arthritis, Rheumatoid/economics , Brazil , Regression Analysis , Cohort Studies , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Antirheumatic Agents/economics , Etanercept/administration & dosage , Etanercept/economics , Middle Aged
Rev. méd. Chile ; 146(1): 39-45, ene. 2018. tab, graf
Article in Spanish | LILACS | ID: biblio-902620


Background: Early recognition of rheumatoid arthritis (RA) provides clinical benefits in terms of remission induction, reduced disease progression, and eventually treatment free remission. Aim: To describe the setting of a Unit devoted exclusively to the recognition and treatment of early RA in patients referred from primary healthcare centers (PHC) in Chile. Materials and Methods: Patients were referred from nine participating PHC from 2014 through 2016. PHC physicians received a formal training to enhance criteria recognition and program adherence. Mandatory referral criteria were an age above 17 years, and arthralgia of less than 1-year duration, plus at least one of the following: morning stiffness of more than 30 minutes, swelling involving more than 3 joints for more than 1 month, a positive squeeze test or abnormal inflammatory serum markers. Results: One hundred twenty patients aged 45 ± 12 years (90% women) were assessed at the early rheumatoid arthritis unit. Median time to referral from PHC to the Unit was 14.6 days. The median duration of symptoms for the overall sample of patients was 10.8 months. RA was identified in 43 patients (36%), with a delay between onset of symptoms and diagnosis of 8.3 months. Regarding the performance of referral criteria, the most sensitive was morning stiffness (80%, sensitivity 95% confidence intervals (CI) 64-89%) and synovitis was the most specific (specificity 83%, 95% CI 72-90%). The positive predictive value of the three clinical criteria altogether was 68.1% (95% CI 47-83%). Conclusions: Institution of an early RA unit was feasible within the Chilean healthcare system enabling the identification of early RA in one-third of patients.

Humans , Male , Female , Middle Aged , Arthritis, Rheumatoid/diagnosis , Comprehensive Health Care , Early Diagnosis , Primary Health Care , Arthritis, Rheumatoid/therapy , Chile , Rheumatic Diseases/classification , Rheumatic Diseases/diagnosis , Rheumatic Diseases/therapy , Sensitivity and Specificity , Health Services Accessibility
Rev. Hosp. Clin. Univ. Chile ; 29(2): 97-108, 2018. tab
Article in Spanish | LILACS | ID: biblio-986659


Rheumatoid arthritis (RA) is a systemic inflammatory disease that primarily affects the joints causing varying degrees of disability. Non-pharmacological management is increasing evidence of its usefulness impacting functionality. Objectives: To characterize the clinical / functional profile of patients with rheumatoid arthritis derived physiatrist assessment in the Clinical Hospital University of Chile. Methods: We reviewed the clinical records of patients with RA derivatives Physical Medicine, extraction demographics, medical history, physical examination and functionality. Statisticians analysis of central tendency, dispersion, absolute and relative frequencies. Results: 85 medical records were analyzed. 88.2% were women with an average age of 54.05 ± 11.42 years. 38.8% have at least one comorbidity. 34.1% of patients takes between 6 and 15 years of disease. The average drug related AR is 5.6 per patient, being more Disease Modifying Antirheumatic Drugs (DMARDs) found. 35.2% presented falls in the past year. Pain is a symptom found in the history and physical examination with a VAE (venous air embolism) 4.4 ± 2.43 at the time of consultation and 6.7 ± 3.3 in crisis. 20% received kinesic therapy and only 7% occupational therapy. 45.3% of patients having a value of HAQ (health assesment questionnaire) who scored as moderate disability, even if their selfperception of independence reaches 65.9%. Conclusion: The analysis allows us to perform a demographic, clinical and functional profile that allows us to guide rehabilitation actions. (AU)

Humans , Male , Female , Adult , Middle Aged , Aged , Arthritis, Rheumatoid/epidemiology , Arthritis, Rheumatoid/pathology , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/rehabilitation , Arthritis, Rheumatoid/therapy , Chile/epidemiology
Rev. chil. reumatol ; 34(3): 122-127, 2018.
Article in Spanish | LILACS | ID: biblio-1254233


El manejo del dolor articular ofrece para la población afectada novedosos suplementos nutricionales que incluyen el colágeno, y cuya extracción es desde variadas fuentes de origen animal, no así de vegetales. Esta revisión tiene como objetivo aclarar qué es el colágeno, su constitución estructural molecular, el rol que cumple en nues-tro organismo y revisar las indicaciones propuestas por la literatura, tanto para la profilaxis como el tratamiento de cuadros reumatológicos de alta prevalencia o impacto funcional, como son Artrosis, Artritis Reumatoidea y Osteoporosis.

Novel nutritional supplements for the management of joint pain have been made available to the population, including collagen, which can not be extracted from plant products, but from a variety of animal sources. This review aims to clarify what it is collagen, the molecular structures that constitute it, the determined role they play in our body and review the indications that the literature proposes both in prophylaxis and treatment, for high prevalence rheumatologic or functional impact, such as osteoarthritis, rheumatoid arthritis and osteoporosis.

Humans , Rheumatic Diseases/therapy , Collagen/therapeutic use , Osteoarthritis/therapy , Osteoporosis/therapy , Arthritis, Rheumatoid/therapy , Extracellular Matrix
Medwave ; 18(6): e7273, 2018.
Article in English, Spanish | LILACS | ID: biblio-948457


Resumen INTRODUCCIÓN: La artritis reumatoide es la artritis inflamatoria más común a nivel mundial. El dolor crónico lleva a pacientes a usar terapias complementarias, entre las cuales se ha planteado la acupuntura MÉTODOS: Para responder esta pregunta utilizamos Epistemonikos, la mayor base de datos de revisiones sistemáticas en salud, la cual es mantenida mediante búsquedas en múltiples fuentes de información, incluyendo MEDLINE, EMBASE, Cochrane, entre otras. Extrajimos los datos desde las revisiones identificadas, reanalizamos los datos de los estudios primarios, realizamos un metanálisis y preparamos una tabla de resúmen de los resultados utilizando el método GRADE. RESULTADOS Y CONCLUSIONES: Identificamos siete revisiones sistemáticas que en conjunto incluyeron 20 estudios primarios, todos correspondientes a ensayos aleatorizados. Concluimos que el uso de acupuntura probablemente tiene un impacto mínimo o nulo en la artritis reumatoide.

Abstract INTRODUCTION: Rheumatoid arthritis is the most common inflammatory arthritis worldwide. Chronic pain leads patients to use complementary therapies, including acupuncture. METHODS: To answer this question we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. RESULTS AND CONCLUSIONS: We identified 7 systematic reviews including 20 studies overall, all of them randomized trials. We concluded the use of acupuncture probably has little or no impact in rheumatoid arthritis.

Humans , Arthritis, Rheumatoid/therapy , Acupuncture Therapy/methods , Chronic Pain/therapy , Randomized Controlled Trials as Topic , Databases, Factual , Treatment Outcome , Chronic Pain/etiology
Rev. bras. reumatol ; 57(3): 204-209, May-June 2017. tab, graf
Article in English | LILACS | ID: biblio-899420


ABSTRACT Introduction: There are few studies that carried out a descriptive and trend analysis based on available data from the Unified Health System (SUS) between pre- and post-free dispensing of pharmacological treatment of rheumatoid arthritis (RA) from the perspective of the public health system, in terms of the direct cost of the disease among adults and elderly residents of the State of Santa Catarina, Brazil. This study aims to characterize the direct cost of medical and surgical procedures before and after the dispensing of drugs in this state. Methods: This is a time series-type study with a cross-sectional survey of data from the Hospital (SIH) and Outpatient (SIA) Information System of SUS during the period from 1996 to 2009. Results: Between 1996 and 2009, the total expenditure for hospital- and outpatient pharmacological treatment of rheumatoid arthritis was R$ 26,659,127.20. After the dispensing of drug treatment by SUS a decrease of 36% in the number of hospital admissions was observed; however, an increase of 19% in clinical procedures was noted. Conclusion: During the observed period, a reduction in the number of hospital admissions for both clinical and orthopedic surgical procedures related to this disease was observed. Nevertheless, there was an increase in the cost of medical admissions.

RESUMO Introdução: Poucos estudos fizeram uma análise descritiva e de tendência dos dados disponíveis do Sistema Único de Saúde (SUS) entre os períodos pré e pós-dispensação gratuita do tratamento medicamentoso da artrite reumatoide (AR) sob a perspectiva do sistema público de saúde em termos de custo direto da doença entre adultos e idosos moradores do Estado de Santa Catarina, Brasil. O presente trabalho tem o objetivo de caracterizar o custo direto de procedimentos clínicos e cirúrgicos antes e após o fornecimento de medicamentos no estado. Métodos: Estudo do tipo série temporal com levantamentos transversais entre 1996 e 2009 dos dados do Sistema de Informação Hospitalar (SIH) e Ambulatorial (SIA) do SUS. Resultados: Entre 1996 a 2009, o gasto total para o tratamento hospitalar e medicamentoso ambulatorial da artrite reumatoide foi de R$ 26.659.127,20. Após a dispensação do tratamento medicamentoso pelo SUS observou-se queda de 36% do número de internações hospitalares. Entretanto notou-se um aumento de 19% nos procedimentos clínicos. Conclusão: No período observado notou-se uma redução do número de internações hospitalares tanto para procedimentos clínicos quanto cirúrgicos ortopédicos relacionadas a essa doença. Apesar disso, ocorreu um aumento do custo das internações clínicas.

Humans , Male , Female , Aged , Aged, 80 and over , Arthritis, Rheumatoid/economics , Health Care Costs/trends , Facilities and Services Utilization/trends , National Health Programs/economics , Arthritis, Rheumatoid/therapy , Brazil , Cross-Sectional Studies , Antirheumatic Agents/economics , Antirheumatic Agents/therapeutic use , Health Care Surveys , Facilities and Services Utilization/economics , Hospitalization/economics , Hospitalization/trends , Middle Aged , National Health Programs/trends
Brasília; CONITEC; jan. 2017. tab, ilus.
Monography in Portuguese | LILACS, BRISA | ID: biblio-837215


Contexto: A AR é uma doença crônica e progressiva, caracterizada pela inflamação da membrana sinovial das articulações. Observa-se um infiltrado linfocítico nas regiões perivasculares e proliferação de células, com consequente angiogênese, hiperplasia sinovial e formação de pannus que levam à destruição articular, cartilagínea e óssea, durante a progressão da AR. O caráter crônico e progressivo da doença pode levar a importante limitação funcional, com perda de capacidade laboral e de qualidade de vida, resultando em significativo impacto pessoal e social, com elevados custos diretos e indiretos. O tratamento precoce de pacientes com AR inicial está associado com uma maior probabilidade de alcance da remissão da doença. Para os pacientes com AR estabelecida, espera-se com o tratamento alcançar a baixa atividade da doença, incluindo a redução da dor e do edema articular, a interrupção do dano ósseo-cartilaginoso, bem como a prevenção de incapacidades e redução da morbimortalidade. Pergunta: O uso de tofacitinibe é eficaz e seguro em pacientes adultos com AR que não obtiveram resposta adequada ao tratamento com metotrexato (MTX) ou outros medicamentos modificadores do curso da doença (MMCD) sintéticos convencionais ou biológicos quando comparado às opções disponíveis atualmente no SUS? Evidências científicas: Em revisões sistemáticas de ensaios clínicos randomizados de fase II e III, tofacitinibe demonstrou melhor eficácia em comparação com MTX e similaridade com os MMCD biológicos para os desfechos ACR 20 e 50, HAQ e redução ou remissão do DAS ou DAS 28. Em relação à segurança não houve diferenças entre tofacitinibe, MTX e MMCD biológico para descontinuação devido a eventos adversos e eventos adversos sérios. No entanto, os pacientes do grupo tofacitinibe apresentaram significativamente menor média de contagem de neutrófilos, aumento da creatinina sérica, aumento de colesterol. LDL (lipoproteína de baixa densidade), maior variação percentual de colesterol LDL e HDL (lipoproteína de alta densidade) e um maior risco de aumento da ALT (alanina aminotranferase) e AST (aspartatoamino transferase) versus placebo ou placebo + MTX. Estudo de comparação indireta realizada pelo demandante mostrou que para ACR20 em 12 semanas, certolizumabe apresentou maior ficácia do que Tofacitinibe. Em 24 semanas e para os demais desfechos observados não foram encontradas diferenças significativas. Para descontinuação por eventos adversos sérios, etanercepte exibiu menor risco de apresentar descontinuação do tratamento do que Tofacitinibe. Também não foram encontradas diferenças com relação a outros eventos adversos. Em estudos observacionais o risco de herpes-zoster foi significativamente maior em usuários de tofacitinibe, sendo aproximadamente o dobro quando comparado ao uso de MMCD biológicos. O risco de perfuração no trato gastrointestinal inferior, foi significantemente superior em usuários de tofacitinibe e tocilizumabe quando comparado aos medicamentos inibidores do fator de necrose tumoral (anti-TNF). As taxas de incidência de câncer observadas permaneceram estáveis ao longo do tempo, não havendo associação entre duração do tratamento com tofacitinibe e risco geral de câncer. Porém, estudos de longo prazo são necessários para avaliar a correlação entre o uso do medicamento e a incidência de câncer. Avaliação econômica: Como o demandante não encontrou diferenças significativas entre Tofacitinibe e os demais biológicos foi feita uma análise de minimização de custos em dois cenários: cenário base ­ que considera apenas os medicamentos; cenário alternativo ­ considera todo o tratamento e inclui custo da medicação, medicamentos concomitantes, administração, acompanhamento e cadeia fria. Para o custo de tofacitinibe 5 mg considerou-se o valor proposto pelo fabricante, de R$ 1.593,18, sem ICMS, para a apresentação de 60 comprimidos (equivalente a um mês de tratamento). A avalição econômica apresenta algumas limitações: 1. O demandante considera que há similaridade com os biológicos em termos de efetividade e segurança, mas há potencial superioridade do certolizumabe em comparação com Tofacitinibe; 2. O demandante considera a necessidade de uso concomitante de MTX em associação com todos os biológicos, mas não com Tofacitinibe. 3. A bula do medicamento sugere o uso concomitante com estatinas e tal custo não foi incluído na análise; 4. Estudos observacionais apontam para uma maior ocorrência de eventos adversos em pacientes em uso de Tofacitinibe em comparação com os demais biológicos, em especial a herpes-zoster. Tal custo não foi incluído na análise. Avaliação de impacto orçamentário: A análise de impacto orçamentário foi dividida entre os cenários base (custo medicamentoso) e cenário alternativo (custo de tratamento), e a população elegível baseou-se em dados do mundo real. O demandante considerou market share progressivo de 2 a 16% em 5 cinco anos. Considerando apenas o custo do medicamento (cenário base), a análise de impacto orçamentário para a inclusão proposta do tofacitinibe no SUS evidencia uma potencial economia de R$64,2 milhões em 5 anos se o produto for incluído na lista de produtos desonerados de PIS e COFINS. Considerando o custo do tratamento (cenário alternativo) a análise de impacto orçamentário feita pelo demandante para a inclusão do tofacitinibe no SUS evidencia uma potencial economia que pode chegar a R$ 73,5 milhões em 5 anos se o produto for incluído na lista de produtos desonerados de PIS e COFINS. Deliberação Final: Aos 30 (trinta) dias do mês de novembro de 2016, os membros da CONITEC recomendaram a incorporação do tofacitinibe para o tratamento de pacientes adultos com artrite reumatoide ativa moderada a grave, conforme Protocolo Clínico e Diretrizes Terapêuticas do Ministério da Saúde e condicionado à negociação de preço. Foi assinado o Registro de Deliberação nº 241/2016. A Portaria Nº 8, de 1º de fevereiro de 2017 - Torna pública a decisão de incorporar o citrato de tofacitinibe para o tratamento de pacientes adultos com artrite reumatoide ativa moderada a grave no âmbito do Sistema Único de Saúde - SUS.

Humans , Adult , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/therapy , Methotrexate/adverse effects , Treatment Failure , Biological Factors , Brazil , Cost-Benefit Analysis/economics , Technology Assessment, Biomedical , Unified Health System